3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3/2012

Reed F. Johnson; Ulas Bagci; Lauren Keith; Xianchun Tang; Daniel J. Mollura; Larry Zeitlin; Jing Qin; Louis Huzella; Christopher J. Bartos; Natasha Bohorova; Ognian Bohorov; Charles Goodman; Do H. Kim; Michael H. Paulty; Jesus Velasco; Kevin J. Whaley; Joshua C. Johnson; James Pettitt; Britini L. Ork; Jeffrey Solomon; Nicholas Oberlander; Quan Zhu; Jiusong Sun; Michael R. Holbrook; Gene G. Olinger; Ralph S. Baric; Lisa E. Hensley; Peter B. Jahrling; Wayne A. Marasco

doi:10.1016/j.virol.2016.01.004

3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3/2012

Reed F. Johnson, Ulas Bagci, Lauren Keith, Xianchun Tang, Daniel J. Mollura, Larry Zeitlin, Jing Qin, Louis Huzella, Christopher J. Bartos, Natasha Bohorova, Ognian Bohorov, Charles Goodman, Do H. Kim, Michael H. Paulty, Jesus Velasco, Kevin J. Whaley, Joshua C. Johnson, James Pettitt, Britini L. Ork, Jeffrey SolomonNicholas Oberlander, Quan Zhu, Jiusong Sun, Michael R. Holbrook, Gene G. Olinger, Ralph S. Baric, Lisa E. Hensley, Peter B. Jahrling, Wayne A. Marasco

Research output: Contribution to journal › Article › peer-review

69 Scopus citations

Abstract

Middle East Respiratory Syndrome Coronavirus (MERS-CoV) was identified in 2012 as the causative agent of a severe, lethal respiratory disease occurring across several countries in the Middle East. To date there have been over 1600 laboratory confirmed cases of MERS-CoV in 26 countries with a case fatality rate of 36%. Given the endemic region, it is possible that MERS-CoV could spread during the annual Hajj pilgrimage, necessitating countermeasure development. In this report, we describe the clinical and radiographic changes of rhesus monkeys following infection with 5×10⁶ PFU MERS-CoV Jordan-n3/2012. Two groups of NHPs were treated with either a human anti-MERS monoclonal antibody 3B11-N or E410-N, an anti-HIV antibody. MERS-CoV Jordan-n3/2012 infection resulted in quantifiable changes by computed tomography, but limited other clinical signs of disease. 3B11-N treated subjects developed significantly reduced lung pathology when compared to infected, untreated subjects, indicating that this antibody may be a suitable MERS-CoV treatment.

Original language	English (US)
Pages (from-to)	49-58
Number of pages	10
Journal	Virology
Volume	490
DOIs	https://doi.org/10.1016/j.virol.2016.01.004
State	Published - Mar 1 2016
Externally published	Yes

Keywords

Animal model, MERS
Antibody therapy
Human monoclonal antibody therapy
MERS-CoV
Respiratory syndrome

ASJC Scopus subject areas

Virology

Access to Document

10.1016/j.virol.2016.01.004

Cite this

Johnson, R. F., Bagci, U., Keith, L., Tang, X., Mollura, D. J., Zeitlin, L., Qin, J., Huzella, L., Bartos, C. J., Bohorova, N., Bohorov, O., Goodman, C., Kim, D. H., Paulty, M. H., Velasco, J., Whaley, K. J., Johnson, J. C., Pettitt, J., Ork, B. L., ... Marasco, W. A. (2016). 3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3/2012. Virology, 490, 49-58. https://doi.org/10.1016/j.virol.2016.01.004

Johnson, RF, Bagci, U, Keith, L, Tang, X, Mollura, DJ, Zeitlin, L, Qin, J, Huzella, L, Bartos, CJ, Bohorova, N, Bohorov, O, Goodman, C, Kim, DH, Paulty, MH, Velasco, J, Whaley, KJ, Johnson, JC, Pettitt, J, Ork, BL, Solomon, J, Oberlander, N, Zhu, Q, Sun, J, Holbrook, MR, Olinger, GG, Baric, RS, Hensley, LE, Jahrling, PB & Marasco, WA 2016, '3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3/2012', Virology, vol. 490, pp. 49-58. https://doi.org/10.1016/j.virol.2016.01.004

@article{e31c927108264f349da5a39af6eb2c6f,

title = "3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3/2012",

abstract = "Middle East Respiratory Syndrome Coronavirus (MERS-CoV) was identified in 2012 as the causative agent of a severe, lethal respiratory disease occurring across several countries in the Middle East. To date there have been over 1600 laboratory confirmed cases of MERS-CoV in 26 countries with a case fatality rate of 36%. Given the endemic region, it is possible that MERS-CoV could spread during the annual Hajj pilgrimage, necessitating countermeasure development. In this report, we describe the clinical and radiographic changes of rhesus monkeys following infection with 5×106 PFU MERS-CoV Jordan-n3/2012. Two groups of NHPs were treated with either a human anti-MERS monoclonal antibody 3B11-N or E410-N, an anti-HIV antibody. MERS-CoV Jordan-n3/2012 infection resulted in quantifiable changes by computed tomography, but limited other clinical signs of disease. 3B11-N treated subjects developed significantly reduced lung pathology when compared to infected, untreated subjects, indicating that this antibody may be a suitable MERS-CoV treatment.",

keywords = "Animal model, MERS, Antibody therapy, Human monoclonal antibody therapy, MERS-CoV, Respiratory syndrome",

author = "Johnson, {Reed F.} and Ulas Bagci and Lauren Keith and Xianchun Tang and Mollura, {Daniel J.} and Larry Zeitlin and Jing Qin and Louis Huzella and Bartos, {Christopher J.} and Natasha Bohorova and Ognian Bohorov and Charles Goodman and Kim, {Do H.} and Paulty, {Michael H.} and Jesus Velasco and Whaley, {Kevin J.} and Johnson, {Joshua C.} and James Pettitt and Ork, {Britini L.} and Jeffrey Solomon and Nicholas Oberlander and Quan Zhu and Jiusong Sun and Holbrook, {Michael R.} and Olinger, {Gene G.} and Baric, {Ralph S.} and Hensley, {Lisa E.} and Jahrling, {Peter B.} and Marasco, {Wayne A.}",

note = "Publisher Copyright: {\textcopyright} 2016 .",

year = "2016",

month = mar,

day = "1",

doi = "10.1016/j.virol.2016.01.004",

language = "English (US)",

volume = "490",

pages = "49--58",

journal = "Virology",

issn = "0042-6822",

publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - 3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3/2012

AU - Johnson, Reed F.

AU - Bagci, Ulas

AU - Keith, Lauren

AU - Tang, Xianchun

AU - Mollura, Daniel J.

AU - Zeitlin, Larry

AU - Qin, Jing

AU - Huzella, Louis

AU - Bartos, Christopher J.

AU - Bohorova, Natasha

AU - Bohorov, Ognian

AU - Goodman, Charles

AU - Kim, Do H.

AU - Paulty, Michael H.

AU - Velasco, Jesus

AU - Whaley, Kevin J.

AU - Johnson, Joshua C.

AU - Pettitt, James

AU - Ork, Britini L.

AU - Solomon, Jeffrey

AU - Oberlander, Nicholas

AU - Zhu, Quan

AU - Sun, Jiusong

AU - Holbrook, Michael R.

AU - Olinger, Gene G.

AU - Baric, Ralph S.

AU - Hensley, Lisa E.

AU - Jahrling, Peter B.

AU - Marasco, Wayne A.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Middle East Respiratory Syndrome Coronavirus (MERS-CoV) was identified in 2012 as the causative agent of a severe, lethal respiratory disease occurring across several countries in the Middle East. To date there have been over 1600 laboratory confirmed cases of MERS-CoV in 26 countries with a case fatality rate of 36%. Given the endemic region, it is possible that MERS-CoV could spread during the annual Hajj pilgrimage, necessitating countermeasure development. In this report, we describe the clinical and radiographic changes of rhesus monkeys following infection with 5×106 PFU MERS-CoV Jordan-n3/2012. Two groups of NHPs were treated with either a human anti-MERS monoclonal antibody 3B11-N or E410-N, an anti-HIV antibody. MERS-CoV Jordan-n3/2012 infection resulted in quantifiable changes by computed tomography, but limited other clinical signs of disease. 3B11-N treated subjects developed significantly reduced lung pathology when compared to infected, untreated subjects, indicating that this antibody may be a suitable MERS-CoV treatment.

AB - Middle East Respiratory Syndrome Coronavirus (MERS-CoV) was identified in 2012 as the causative agent of a severe, lethal respiratory disease occurring across several countries in the Middle East. To date there have been over 1600 laboratory confirmed cases of MERS-CoV in 26 countries with a case fatality rate of 36%. Given the endemic region, it is possible that MERS-CoV could spread during the annual Hajj pilgrimage, necessitating countermeasure development. In this report, we describe the clinical and radiographic changes of rhesus monkeys following infection with 5×106 PFU MERS-CoV Jordan-n3/2012. Two groups of NHPs were treated with either a human anti-MERS monoclonal antibody 3B11-N or E410-N, an anti-HIV antibody. MERS-CoV Jordan-n3/2012 infection resulted in quantifiable changes by computed tomography, but limited other clinical signs of disease. 3B11-N treated subjects developed significantly reduced lung pathology when compared to infected, untreated subjects, indicating that this antibody may be a suitable MERS-CoV treatment.

KW - Animal model, MERS

KW - Antibody therapy

KW - Human monoclonal antibody therapy

KW - MERS-CoV

KW - Respiratory syndrome

UR - http://www.scopus.com/inward/record.url?scp=84961381392&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961381392&partnerID=8YFLogxK

U2 - 10.1016/j.virol.2016.01.004

DO - 10.1016/j.virol.2016.01.004

M3 - Article

C2 - 26828465

AN - SCOPUS:84961381392

SN - 0042-6822

VL - 490

SP - 49

EP - 58

JO - Virology

JF - Virology

ER -

3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3/2012

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this